Rachele Ciccocioppo, Giuseppina C Cangemi, Peter Kruzliak, Alessandra Gallia, Elena Betti, Carla Badulli, Miryam Martinetti, Marila Cervio, Alessandro Pecci, Valeria Bozzi, Paolo Dionigi, Livia Visai, Antonella Gurrado, Costanza Alvisi, Cristina Picone, Manuela Monti, Maria E Bernardo, Paolo Gobbi, Gino R Corazza
INTRODUCTION: Crohn's disease (CD) is a disabling chronic enteropathy sustained by a harmful T-cell response toward antigens of the gut microbiota in genetically susceptible subjects. Growing evidence highlights the safety and possible efficacy of mesenchymal stem cells (MSCs) as a new therapeutic tool for this condition. Therefore, we aimed to investigate the effects of bone marrow-derived MSCs on pathogenic T cells with a view to clinical application. METHODS: T-cell lines from both inflamed and non-inflamed colonic mucosal specimens of CD patients and from healthy mucosa of control subjects were grown with the antigen muramyl-dipeptide in the absence or presence of donors' MSCs...
July 24, 2015: Stem Cell Research & Therapy